GLP-1s and Cancer Risk: What ASCO 2026 Showed

The 2026 American Society of Clinical Oncology Annual Meeting (ASCO 2026), held May 29 – June 2 in Chicago, featured multiple presentations on a question that has been quietly gathering momentum in the oncology research literature: do GLP-1 receptor agonists have anticancer effects beyond their established metabolic and weight management indications? Three substantial real-world studies presented at the conference — from Cleveland Clinic, Penn Medicine, and Roswell Park Comprehensive Cancer Center — added meaningful evidence to an emerging hypothesis that GLP-1 use may be associated with reduced cancer progression and incidence in certain obesity-related cancers.

This article addresses what the three ASCO 2026 studies showed, the important observational research caveats that apply to all three, and what the findings mean for the broader research understanding of GLP-1 receptor agonist pharmacology. The article is news + analysis. All studies discussed are observational research that establish hypotheses requiring future prospective trials — they do not constitute evidence sufficient for clinical decision-making, and they do not change the regulatory framing for any GLP-1 research peptide in any way.

Why This Research Is Happening Now

GLP-1 receptor agonists — including Semaglutide, Tirzepatide, and the investigational Retatrutide — have rapidly expanded from their original type 2 diabetes indications into obesity, cardiovascular risk reduction, kidney disease, and obstructive sleep apnea applications. As patient populations on these compounds have grown into the millions, real-world evidence cohorts large enough to detect signals across multiple disease domains have become available. Cancer outcomes are one of the most significant areas of active investigation in this expanded evidence base.

The biological hypothesis underlying GLP-1/cancer research operates through two non-mutually-exclusive pathways. Direct antitumor mechanism: GLP-1 receptors are expressed on various tissue types beyond pancreas and brain, including some tumor tissues, and GLP-1 signaling has been demonstrated to influence cellular proliferation, apoptosis, and inflammatory responses in laboratory research models. Indirect mechanism via weight loss: Obesity is a well-established risk factor for at least 13 different cancer types, and substantial weight loss through any mechanism may reduce cancer risk through reduced inflammatory burden, normalized hormone levels, and improved metabolic profiles. Real-world cohorts cannot easily distinguish between these mechanisms — a question that remains a primary focus for future prospective research.

The Cleveland Clinic Metastatic Progression Study

The largest of the three ASCO 2026 GLP-1/cancer presentations came from Cleveland Clinic investigators who analyzed real-world outcomes in 12,112 patients across seven obesity-related cancers [Ref. 1]. The study compared cancer progression outcomes between patients who started GLP-1 receptor agonists after their cancer diagnosis versus patients who started DPP-4 inhibitors (gliptins) — the latter group serving as an active comparator population also being treated for type 2 diabetes but with a different drug mechanism.

The cancers studied: breast adenocarcinoma, prostate adenocarcinoma, non-small cell lung cancer, colorectal adenocarcinoma, hepatocellular (liver) carcinoma, renal cell (kidney) carcinoma, and pancreatic adenocarcinoma. The primary endpoint was metastatic progression to stage 4 disease.

Reported findings, as covered in independent journalism [Ref. 3] and the ASCO press release [Ref. 1]:

The investigators also reported that GLP-1 receptor expression in tumor tissue was associated with overall survival — a finding that supports the direct mechanism hypothesis but does not establish it [Ref. 4].

The 50% lung cancer reduction and 43% breast cancer reduction are striking effect sizes if they replicate in prospective research. Both findings come with important observational research limitations: this is a real-world data study, not a randomized controlled trial; treatment assignment was not random; and unmeasured confounding variables may explain part or all of the observed effect.

The Penn Medicine Breast Cancer Prevention Study

The Penn Medicine team, led by Elizabeth McDonald, MD, PhD at the University of Pennsylvania Perelman School of Medicine and the Abramson Cancer Center, reported on a different question: not whether GLP-1 use reduces progression in patients who already have cancer, but whether GLP-1 use is associated with reduced cancer incidence in patients without prior cancer diagnosis [Ref. 2].

The Penn Medicine retrospective analysis examined more than 110,000 women between the ages of 45 and 80. Compared with women not taking GLP-1 medications, those who did were approximately 30% less likely to develop breast cancer over the follow-up period [Ref. 2].

The finding is significant for two reasons. First, it addresses a different research question (incidence) than the Cleveland Clinic study (progression), and convergent findings across both questions support stronger inferences than either finding alone would support. Second, the Penn Medicine team has announced plans to launch a multi-site clinical trial to prospectively evaluate whether GLP-1 use reduces breast cancer incidence [Ref. 2] — establishing the pathway from observational signal to prospective evidence that GLP-1/cancer research will need to follow before therapeutic implications can be drawn.

The Penn Medicine study is also subject to observational research limitations. The most important is the substantial weight loss that GLP-1 users experience: any prevention effect could be mediated through weight loss rather than through direct GLP-1 signaling. A prospective trial would need to account for this through trial design — either by enrolling participants on stable weight or by including comparator groups achieving similar weight loss through other means.

The Roswell Park HR+ Breast Cancer Study

The third major ASCO 2026 GLP-1/cancer study came from Zunairah Shah, MBBS and colleagues at Roswell Park Comprehensive Cancer Center. The Roswell Park real-world analysis of nearly 150,000 women specifically examined hormone receptor-positive (HR+), HER2-negative breast cancer — the most common breast cancer subtype, accounting for approximately two-thirds of all breast cancer diagnoses.

The Roswell Park findings indicated that GLP-1 receptor agonist exposure was associated with a modest but significant reduction in incident HR+/HER2-negative breast cancer, and a marked improvement in overall survival among non-diabetic women with elevated BMI (25-35 kg/m²) [Ref. 4].

The Roswell Park study’s specific contribution to the broader GLP-1/cancer literature is the focus on non-diabetic women with elevated BMI. Most GLP-1 patient populations until recently consisted predominantly of diabetic patients (the original GLP-1 indication). With the expansion of GLP-1 indications into obesity treatment without diabetes, the non-diabetic obese population has become a distinct study group. The Roswell Park finding that survival benefits extend into this population — distinct from a diabetic cohort — supports the hypothesis that the observed cancer outcomes are not specifically diabetes-mediated.

The investigators noted that whether the observed effects are direct antitumor mechanisms or indirect benefits from weight loss and cardiometabolic improvement remains unclear, and additional prospective trial research is needed [Ref. 4].

Supporting Peer-Reviewed Evidence

The three ASCO 2026 presentations build on a growing peer-reviewed literature base examining GLP-1 and cancer outcomes. A 2025 retrospective cohort study by Chuang and colleagues published in Oncology Research analyzed electronic health records from the TriNetX U.S. research network, examining whether early initiation of GLP-1 receptor agonist therapy (within three months of type 2 diabetes diagnosis) altered subsequent cancer risk [Ref. 5]. The study used propensity score matching to compare 183,264 GLP-1 RA users against 183,264 matched non-users, with stratified analyses by baseline body mass index.

The Chuang study and similar peer-reviewed work establish the scientific foundation that supports the conference-presented findings — converging real-world evidence across multiple large cohorts from multiple research groups using different methodologies. The cumulative pattern is more meaningful than any single study, though all of the work remains observational rather than randomized controlled trial evidence.

A separate January 2026 study presented at an ASCO regional meeting reported that GLP-1 users had 36% lower colon cancer rates than aspirin users in a real-world data analysis. While limited to a single comparator drug, the finding aligned with the broader pattern of GLP-1 use being associated with reduced cancer outcomes across multiple obesity-related cancer types.

The Observational Research Caveats That Apply to All Three Studies

The ASCO 2026 findings are scientifically interesting but require careful interpretation. Several observational research limitations apply to all three studies and to the broader emerging literature.

Causation versus association. Observational research can identify associations but cannot establish causal effects. Patients who start GLP-1 medications differ systematically from patients who do not — in motivation to engage with healthcare, in baseline metabolic health, in BMI distribution, in adherence behaviors, in concurrent treatments, and in countless other ways that may be only partially captured in healthcare records. Any of these unmeasured factors could explain observed differences in cancer outcomes.

Confounding by indication. The patients receiving GLP-1 medications are receiving them for specific medical reasons (diabetes, obesity, cardiometabolic risk). The patients in comparator groups are receiving alternative treatments (DPP-4 inhibitors, insulin, or no treatment) for different reasons, with different baseline characteristics. Statistical adjustment can partially address this but cannot fully eliminate confounding by indication.

Time-dependent confounding. Cancer is a slow-developing disease, and the relevant exposure window for cancer prevention or progression may not align with the relatively short follow-up periods available in real-world data studies of newer GLP-1 medications. Effects observed early may not persist; effects requiring longer exposure may be missed.

Direct versus indirect mechanism uncertainty. None of the three ASCO 2026 studies can distinguish between direct antitumor effects of GLP-1 signaling and indirect effects mediated through weight loss, glycemic control, or cardiometabolic improvement. This is not a small distinction — it determines whether GLP-1 medications might function as cancer prevention agents specifically, or whether any modality producing comparable weight loss would produce comparable cancer outcomes.

Conference presentation versus peer review. ASCO conference presentations have not yet undergone the full peer review process required for journal publication. The Cleveland Clinic, Penn Medicine, and Roswell Park studies will need peer-reviewed publication before they can be considered scientifically established findings.

What This Means for Research Understanding

Despite the observational caveats, the convergent findings from multiple major research institutions presenting at the same conference within days of each other establish a research signal that warrants serious attention.

The cumulative picture from the ASCO 2026 findings, the supporting peer-reviewed literature [Ref. 5], and the earlier 2026 work on colon cancer and liver cancer outcomes suggests that GLP-1 receptor agonist use is associated with measurable reductions in cancer progression and incidence across multiple obesity-related cancer types. The effect sizes (30-50% reductions in some specific findings) are large enough to be clinically meaningful if they replicate in prospective research.

The next research step is prospective randomized controlled trials, and Penn Medicine has announced plans to launch one focused on breast cancer prevention. Trial design will need to address several questions:

• Does GLP-1 effect on cancer outcomes depend on weight loss magnitude, or is it observed at any weight loss level?
• Do different GLP-1 compounds produce different effects (Semaglutide vs Tirzepatide vs others)?
• Is the effect dose-dependent within compounds?
• Does the effect vary by cancer type and tumor characteristics?
• Are the effects specific to GLP-1 receptor activation, or would they extend to GIP and glucagon receptor co-activation in dual and triple agonists?

The Retatrutide TRIUMPH program covered in our TRIUMPH-1 Phase 3 results article will eventually generate data relevant to some of these questions, particularly the triple-agonist mechanism question. Larger and longer trials specifically designed to assess cancer endpoints are years away from reading out.

What This Does NOT Mean

Several points are important to be explicit about.

GLP-1 compounds are not cancer treatments. The observed associations do not establish that GLP-1 medications are effective treatments for cancer. None of the compounds have FDA, Health Canada, or any other regulatory agency approval for cancer prevention or treatment indications.

The findings do not warrant clinical practice changes. Patients and clinicians should not change cancer screening, prevention, or treatment decisions based on observational research findings. Routine cancer screening (mammography, colonoscopy, etc.) remains the foundation of cancer prevention and early detection regardless of whether a patient is on GLP-1 medications.

Research-grade compound use is unchanged. Research-grade Semaglutide, Tirzepatide, and Retatrutide sold by Kinetic Compounds are for laboratory research purposes only. The ASCO 2026 findings concern approved pharmaceutical products used in patients with specific medical indications — not research-grade material used in laboratory contexts. The findings have no implication for research-grade compound use.

The mechanism question matters. If observed effects are entirely mediated through weight loss, then any intervention producing comparable weight loss (bariatric surgery, sustained dietary intervention, other weight-loss medications) might produce comparable cancer outcomes. If observed effects are partly direct GLP-1 signaling effects, then GLP-1 medications might have a specific role in cancer prevention strategies that other weight-loss interventions would not have. Current research cannot distinguish between these possibilities.

Sourcing Research-Grade Compounds

For researchers studying GLP-1-class compounds in laboratory contexts, Semaglutide, Tirzepatide, and Retatrutide are available through the Kinetic Compounds catalog with batch-specific Certificates of Analysis from Janoshik Analytical published on each product page.

Complete mechanism and research background for these compounds is covered in our individual deep dives: Semaglutide, Tirzepatide, and Retatrutide, with head-to-head comparison in our GLP-1 research comparison.

Research-grade material is intended exclusively for laboratory research and is not a substitute for any approved pharmaceutical product. The clinical research findings discussed in this article concern pharmaceutical product use in patients — not research-grade compound applications.

For research background on the GLP-1 compounds discussed in this article, see our deep dives on Semaglutide, Tirzepatide, and Retatrutide, with head-to-head comparison in our GLP-1 research comparison. Research-grade material for laboratory research is available through our research peptide catalog with current Certificates of Analysis on every product page.